Harbor Capital Advisors Inc. Acquires Shares of 97,543 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Harbor Capital Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 97,543 shares of the company’s stock, valued at approximately $2,438,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Acadian Asset Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 167.8% during the first quarter. Acadian Asset Management LLC now owns 164,568 shares of the company’s stock worth $3,240,000 after buying an additional 103,120 shares during the period. Sei Investments Co. acquired a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $1,450,000. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after acquiring an additional 157,741 shares during the period. SG Americas Securities LLC grew its stake in shares of Kiniksa Pharmaceuticals by 8.1% in the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after purchasing an additional 1,435 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $34.60.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares of the company’s stock, valued at $3,226,805.01. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares of the company’s stock, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,692 shares of company stock valued at $2,950,315 in the last quarter. 54.57% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $21.48 on Tuesday. The company has a market cap of $1.53 billion, a P/E ratio of -156.70 and a beta of 0.35. Kiniksa Pharmaceuticals, Ltd. has a one year low of $14.12 and a one year high of $28.15. The business has a fifty day moving average of $25.40 and a two-hundred day moving average of $22.53.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. During the same period in the prior year, the firm posted ($0.20) EPS. The firm’s quarterly revenue was up 67.4% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.47 EPS for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.